1.0KFF Health Newshttps://kffhealthnews.orgkhnkithttps://kffhealthnews.org/news/author/khnkit/New Oral Heart Disease Drug Gains FDA Approval - KFF Health Newsrich600338<blockquote class="wp-embedded-content" data-secret="0zgO1pQH2F"><a href="https://kffhealthnews.org/morning-breakout/new-oral-heart-disease-drug-gains-fda-approval/">New Oral Heart Disease Drug Gains FDA Approval</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://kffhealthnews.org/morning-breakout/new-oral-heart-disease-drug-gains-fda-approval/embed/#?secret=0zgO1pQH2F" width="600" height="338" title="“New Oral Heart Disease Drug Gains FDA Approval” — KFF Health News" data-secret="0zgO1pQH2F" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
The new drug, called Mavacamten, tackles hypertrophic cardiomyopathy which affects about 1 in 500 people and is the most common cause of sudden cardiac death in young people. AstraZeneca, Baxter International, Merck and shareholder reluctance at opening covid patents, and more are also in health industry news.